Mark Schluchter

Mark Schluchter

Auto-generated profile, based on publicly available information

Mark Schluchter

Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
CBC. Badve
C. Badve
AYA. Yu
A. Yu
SDS. Dastmalchian
S. Dastmalchian
MRM. Rogers
M. Rogers
DMD. Ma
D. Ma
VGVikas Gulani
Vikas Gulani
BACKGROUND AND PURPOSE: MR fingerprinting allows rapid simultaneous quantification of T1 and T2 relaxation times. This study assessed the utility of MR fingerprinting in differentiating common types of adult intra-axial brain tumors. MATERIALS AND METHODS: MR fingerprinting acquisition was performed in 31 patients with untreated intra-axial brain tumors: 17 glioblastomas, 6 World Health Organization grade II lower grade gliomas, and 8 metastases. T1, T2 of the solid tumor, immediate peritumoral white matter, and contralateral white matter were summarized within each ROI. Statistical comparisons on mean, SD, skewness, and kurtosis were performed by using the univariate Wilcoxon rank sum test across various tumor types. Bonferroni correction was used to correct for multiple-comparison testing. Multivariable logistic regression analysis was performed for discrimination between glioblastomas and metastases, and area under the receiver operator curve was calculated. RESULTS: Mean T2 values could differentiate solid tumor regions of lower grade gliomas from metastases (mean, 172 ± 53 ms, and 105 ± 27 ms, respectively; P = .004, significant after Bonferroni correction). The mean T1 of peritumoral white matter surrounding lower grade gliomas differed from peritumoral white matter around glioblastomas (mean, 1066 ± 218 ms, and 1578 ± 331 ms, respectively; P = .004, significant after Bonferroni correction). Logistic regression analysis revealed that the mean T2 of solid tumor offered the best separation between glioblastomas and metastases with an area under the curve of 0.86 (95% CI, 0.69–1.00; P < .0001). CONCLUSIONS: MR fingerprinting allows rapid simultaneous T1 and T2 measurement in brain tumors and surrounding tissues. MR fingerprinting–based relaxometry can identify quantitative differences between solid tumor regions of lower grade gliomas and metastases and between peritumoral regions of glioblastomas and lower grade gliomas.

19 July 2012 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
JLJonathan S Litt
Jonathan S Litt
HTH. Gerry Taylor
H. Gerry Taylor
SMSeunghee Margevicius
Seunghee Margevicius
MSMark Schluchter
Mark Schluchter
LALaura Andreias
Laura Andreias
MHMaureen Hack
Maureen Hack

1 October 2006 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MSMark D. Schluchter
Mark D. Schluchter
MKMichael W. Konstan
Michael W. Konstan
MDMitchell L. Drumm
Mitchell L. Drumm
JYJames R. Yankaskas
James R. Yankaskas
MKMichael R. Knowles
Michael R. Knowles
Rationale: The study of genetic modifiers in cystic fibrosis (CF) lung disease requires rigorous phenotyping. One type of genetic association study design compares polymorphisms in patients at extremes of phenotype, requiring accurate classification of pulmonary disease at varying ages. Objective: To evaluate approaches to quantify severity of pulmonary disease and their ability to discriminate between patients with CF at the extremes of phenotype. Methods: ΔF508 homozygotes (n = 828) were initially classified as “severe” (approximate lowest quartile of FEV1 (% pred) for age, 8–25 yr) or “mild” disease (highest quartile of FEV1 for age, ⩾ 15 yr). FEV1 measurements from the 5 yr before enrollment (total = 18,501 measurements; average 23 per subject) were analyzed with mixed models, and patient-specific estimates of FEV1 (% pred) at ages 5, 10, 15, 20, and 25 yr and slope of FEV1 versus age were examined for their ability to discriminate between groups using receiver operating characteristics (ROC) curve areas. Results: Logistic regression of severity group on mixed model (empirical Bayes) estimates of intercept and slope of FEV1 (% pred) versus age discriminated better than did classification using FEV1 slope alone (ROC area = 0.995 vs. 0.821) and was equivalent to using estimated FEV1 at 20 yr of age as a single discriminator. The estimated survival percentile from a joint survival/longitudinal model provided equally good classification (ROC area = 0.994). Conclusions: In CF, estimated FEV1 (% pred) at 20 yr of age and the estimated survival percentile are useful indices of pulmonary disease severity.

1 September 2019 in Radiology
Verified
Journal Article
Closed access
APAnanya Panda
Ananya Panda
VOVerena C. Obmann
Verena C. Obmann
WLWei-Ching Lo
Wei-Ching Lo
SMSeunghee Margevicius
Seunghee Margevicius
YJYun Jiang
Yun Jiang
VGVikas Gulani
Vikas Gulani
In the transition zone, prostate cancer T1 and T2 relaxation times observed with MR fingerprinting and apparent diffusion coefficients obtained with diffusion MRI are lower than those in noncancers... BackgroundPreliminary studies have shown that MR fingerprinting–based relaxometry combined with apparent diffusion coefficient (ADC) mapping can be used to differentiate normal peripheral zone from...

22 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
XWXinning Wang
Xinning Wang
ASAditi Ashish Shirke
Aditi Ashish Shirke
CUCase Western Reserve University
Case Western Reserve University
RSRongcan Sun
Rongcan Sun
GRGopalakrishnan Ramamurthy
Gopalakrishnan Ramamurthy
JBJames Basilion
James Basilion
Metastatic castration-resistant prostate cancer poses a serious clinical problem with poor outcomes and remains a deadly disease. New targeted treatment options are urgently needed. PSMA is highly expressed in prostate cancer and has been an attractive biomarker for the treatment of prostate cancer. In this study, we explored the feasibility of targeted delivery of an antimitotic drug, monomethyl auristatin E (MMAE), to tumor tissue using a small-molecule based PSMA lig-and. With the aid of Cy5.5, we found that a cleavable linker is vital for the antitumor activity of the ligand–drug conjugate and have developed a new PSMA-targeting prodrug, PSMA-1-VcMMAE. In in vitro studies, PSMA-1-VcMMAE was 48-fold more potent in killing PSMA-positive PC3pip cells than killing PSMA-negative PC3flu cells. In in vivo studies, PSMA-1-VcMMAE significantly inhibited tumor growth leading to prolonged animal survival in different animal models, including metastatic prostate cancer models. Compared to anti-PSMA antibody-MMAE conjugate (PSMA-ADC) and MMAE, PSMA-1-VcMMAE had over a 10-fold improved maximum tolerated dose, resulting in improved therapeutic index. The small molecule–drug conjugates reported here can be easily synthesized and are more cost efficient than anti-body–drug conjugates. The therapeutic profile of the PSMA-1-VcMMAE encourages further clin-ical development for the treatment of advanced prostate cancer.

1 October 2009 in Journal of Perinatology
Verified
Journal Article
Open access
JMJ Madden
J Madden
KKK Kobaly
K Kobaly
NMNori Mercuri Minich
Nori Mercuri Minich
MSM Schluchter
M Schluchter
DWD Wilson-Costello
D Wilson-Costello
MHM Hack
M Hack
Objective: Study Design: Result: Conclusion: